PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16644314-5 2006 RESULTS: At 16 weeks, more patients achieved their LDL-C target by switching to rosuvastatin 10 mg than staying on atorvastatin 10 mg (66% vs 42%, P < .001) or simvastatin 20 mg (73% vs 32%, P < .001). Rosuvastatin Calcium 80-92 component of oligomeric golgi complex 2 Homo sapiens 51-56 16644314-6 2006 Changing to rosuvastatin 20 mg brought more patients to their LDL-C target than staying on atorvastatin 20 mg (79% vs 64%, P < .001) or simvastatin 40 mg (84% vs 56%, P < .001). Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 62-67 16644314-9 2006 Switching to rosuvastatin produced greater reductions in LDL-C, total cholesterol, non-HDL-C, apolipoprotein B, and lipid ratios. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 57-62 16533939-17 2006 CONCLUSIONS: Very high-intensity statin therapy using rosuvastatin 40 mg/d achieved an average LDL-C of 60.8 mg/dL and increased HDL-C by 14.7%, resulting in significant regression of atherosclerosis for all 3 prespecified IVUS measures of disease burden. Rosuvastatin Calcium 54-66 component of oligomeric golgi complex 2 Homo sapiens 95-100 16186052-9 2005 RESULTS: Treatment with rosuvastatin 10 mg costs 1.85 per 1% reduction in LDL-C, compared with 2.37 per 1% reduction with atorvastatin 10 mg. Rosuvastatin Calcium 24-36 component of oligomeric golgi complex 2 Homo sapiens 74-79 16143705-4 2005 LDL-C was reduced significantly more in patients receiving rosuvastatin 10 mg when compared with those receiving atorvastatin 10 mg at 6 weeks [intention-to-treat (ITT) population by randomized treatment: 41.7 vs. 35.7%, P < 0.001; ITT population by as-allocated treatment: 42.7 vs. 36.6%, P < 0.001]. Rosuvastatin Calcium 59-71 component of oligomeric golgi complex 2 Homo sapiens 0-5 16143705-5 2005 Significant LDL-C reductions were also observed in patients receiving rosuvastatin when compared with those receiving atorvastatin at 12 weeks (48.9 vs. 42.5%, P < 0.001). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 12-17 16143705-6 2005 More patients achieved LDL-C goals with rosuvastatin when compared with atorvastatin. Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 23-28 16143705-9 2005 CONCLUSION: At equivalent doses, rosuvastatin had a significantly greater effect than atorvastatin in lowering LDL-C and improving the lipid profile and was well tolerated in patients with the metabolic syndrome. Rosuvastatin Calcium 33-45 component of oligomeric golgi complex 2 Homo sapiens 111-116 16186052-2 2005 The introduction of a highly efficacious new statin, rosuvastatin, may enable more patients to be treated to LDL-C goal within a fixed budget. Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 109-114 16186052-3 2005 OBJECTIVES: To compare the cost-effectiveness of rosuvastatin 10 mg and atorvastatin 10 mg in lowering LDL-C and achieving guideline goals after 12 weeks of treatment. Rosuvastatin Calcium 49-61 component of oligomeric golgi complex 2 Homo sapiens 103-108 16186052-10 2005 The average costs per patient treated to the European LDL-C goals were 130.18 for rosuvastatin 10 mg and 242.44 for atorvastatin 10 mg. Rosuvastatin Calcium 82-94 component of oligomeric golgi complex 2 Homo sapiens 54-59 16186052-12 2005 CONCLUSIONS: Rosuvastatin has the same acquisition costs as and is more efficacious than atorvastatin in lowering LDL-C and treating patients to target LDL-C levels. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 114-119 16186052-12 2005 CONCLUSIONS: Rosuvastatin has the same acquisition costs as and is more efficacious than atorvastatin in lowering LDL-C and treating patients to target LDL-C levels. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 152-157 15639694-12 2004 Compared with atorvastatin, rosuvastatin was associated with significantly greater reductions in LDL-C and TC (both, P < 0.05), and with a significantly greater increase in high-density lipoprotein cholesterol level (P < (105). Rosuvastatin Calcium 28-40 component of oligomeric golgi complex 2 Homo sapiens 97-102 15707472-6 2005 The data show that rosuvastatin 5 mg is highly effective in lowering LDL-C to recommended levels for most patients (mean reductions ranging from 42 to 52%). Rosuvastatin Calcium 19-31 component of oligomeric golgi complex 2 Homo sapiens 69-74 15707472-8 2005 The 5-mg dose of rosuvastatin dose also produces greater reductions in LDL-C and larger increases in HDL-C than recommended initial doses of atorvastatin, simvastatin or pravastatin (for LDL-C reductions, p <0.001 vs. atorvastatin 10 mg, simvastatin 20 mg and pravastatin 20 mg; for HDL-C elevations, p <0.01 vs. atorvastatin 10 mg). Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 71-76 15707472-8 2005 The 5-mg dose of rosuvastatin dose also produces greater reductions in LDL-C and larger increases in HDL-C than recommended initial doses of atorvastatin, simvastatin or pravastatin (for LDL-C reductions, p <0.001 vs. atorvastatin 10 mg, simvastatin 20 mg and pravastatin 20 mg; for HDL-C elevations, p <0.01 vs. atorvastatin 10 mg). Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 187-192 15707472-9 2005 These results demonstrate that rosuvastatin 5 mg produces favourable effects on the lipid profile and helps more patients achieve LDL-C goals than comparator statins. Rosuvastatin Calcium 31-43 component of oligomeric golgi complex 2 Homo sapiens 130-135 16128507-5 2005 DATA SYNTHESIS: Multiple clinical trials have revealed that use of rosuvastatin is associated with greater reductions in low-density lipoprotein cholesterol (LDL-C) across the dose range of 5-40 mg/day than any other currently available statins. Rosuvastatin Calcium 67-79 component of oligomeric golgi complex 2 Homo sapiens 158-163 16128507-10 2005 Rosuvastatin may allow more patients to achieve their LDL-C goals than any other statin and at a lower dose than other agents. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 54-59 15639694-13 2004 A greater proportion of patients in the rosuvastatin group compared with the atorvastatin group reached the 1998 goals for LDL-C (83.4% vs 683%; P < 0.001) and TC (76.4% vs 59.5%; P < 0.001). Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 123-128 15639694-14 2004 Also, compared with the atorvastatin group, greater proportions of patients in the rosuvastatin group achieved the 2003 JTF goals for LDL-C and TC (both, P < 0.001). Rosuvastatin Calcium 83-95 component of oligomeric golgi complex 2 Homo sapiens 134-139 15639694-16 2004 CONCLUSIONS: In this study of selected patients at high risk for CHD and with primary hypercholesterolemia, rosuvastatin 10 mg/d for 12 weeks was associated with significantly greater reductions in LDL-C and TC levels compared with atorvastatin 10 mg/d. Rosuvastatin Calcium 108-120 component of oligomeric golgi complex 2 Homo sapiens 198-203 19667621-6 2003 Atorvastatin is the most effective of the currently available statins, but rosuvastatin, an agent in development, appears to be even more effective and allows patients with mild-to-moderate hypercholesterolemia or heterozygous familial hypercholesterolemia to achieve the recommended LDL-C targets. Rosuvastatin Calcium 75-87 component of oligomeric golgi complex 2 Homo sapiens 284-289 16035394-4 2004 The most recent statin to be introduced, rosuvastatin, has been shown to be the most effective at lowering LDL-C, as well as consistently raising HDL-C across the 10-40 mg dose range. Rosuvastatin Calcium 41-53 component of oligomeric golgi complex 2 Homo sapiens 107-112 16035394-7 2004 URANUS and ANDROMEDA showed rosuvastatin to be more effective than atorvastatin at reducing LDL-C and achieving treatment target goals. Rosuvastatin Calcium 28-40 component of oligomeric golgi complex 2 Homo sapiens 92-97 16035394-8 2004 CORALL demonstrated rosuvastatin 10, 20 and 40 mg to be more effective at lowering LDL-C than 20, 40 and 80 mg of atorvastatin, respectively. Rosuvastatin Calcium 20-32 component of oligomeric golgi complex 2 Homo sapiens 83-88 15531000-1 2004 BACKGROUND: Rosuvastatin is a new statin indicated to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 99-134 15531000-1 2004 BACKGROUND: Rosuvastatin is a new statin indicated to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 136-141 15531000-5 2004 RESULTS: Rosuvastatin 10 to 40 mg/d reduced LDL-C by 43% to 63% (P < 0.05). Rosuvastatin Calcium 9-21 component of oligomeric golgi complex 2 Homo sapiens 44-49 15531000-6 2004 Compared with other statins, rosuvastatin had the highest dose-to-dose potency in lowering LDL-C (reduction of 60% vs 50% with atorvastatin, 40% with simvastatin, 30% with pravastatin or lovastatin, and 20% with fluvastatin) and better efficacy in raising HDL-C (increase of approximately 10% vs approximately 5% with other statins; P < 0.05). Rosuvastatin Calcium 29-41 component of oligomeric golgi complex 2 Homo sapiens 91-96 15531000-7 2004 Rosuvastatin enabled significantly more patients to achieve the National Cholesterol Education Program (NCEP) goals for LDL-C with lower doses (P < 0.05). Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 120-125 15531000-13 2004 Recent evidence suggests the need for an even lower LDL-C goal than that being recommended by the NCEP Based on the studies included in this review, rosuvastatin may help patients achieve optimal goals early with lower dosages, thus reducing the need for dose titration or combination therapy. Rosuvastatin Calcium 149-161 component of oligomeric golgi complex 2 Homo sapiens 52-57 15215813-1 2004 BACKGROUND: This double-blind, multicenter, randomized trial compared rosuvastatin and atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and a high risk of coronary heart disease. Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 150-155 15215813-4 2004 RESULTS: At 24 weeks, LDL-C was reduced significantly more with 80 mg rosuvastatin (combined rosuvastatin group) than with atorvastatin 80 mg (60% vs 52% [P <.001]). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 22-27 15215813-5 2004 At 12 weeks, rosuvastatin 5 and 10 mg reduced LDL-C significantly more than atorvastatin 10 mg (40% [P <.01], 47% [P <.001] vs 35%). Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 46-51 15215813-6 2004 At 18 weeks, LDL-C reductions were also significantly greater in both rosuvastatin groups than in the atorvastatin group (52% [P <.01], 59% [P <.001] vs 47%). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 13-18 15215813-7 2004 Consequently, more patients receiving rosuvastatin achieved LDL-C goals. Rosuvastatin Calcium 38-50 component of oligomeric golgi complex 2 Homo sapiens 60-65 15161326-7 2004 Rosuvastatin is a potent, hydrophilic enantiomeric statin producing reductions in LDL-C of up to 55%, with about 80% of patients reaching European LDL-C treatment targets at the 10 mg/day dosage. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 82-87 15161326-7 2004 Rosuvastatin is a potent, hydrophilic enantiomeric statin producing reductions in LDL-C of up to 55%, with about 80% of patients reaching European LDL-C treatment targets at the 10 mg/day dosage. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 147-152 11383378-1 2001 In a 2-stage, placebo-controlled, Phase 2 dose-ranging trial evaluating the new statin rosuvastatin in men and postmenopausal women with hypercholesterolemia, the agent was found to reduce low-density lipoprotein cholesterol (LDL-C) levels in a dose-related manner. Rosuvastatin Calcium 87-99 component of oligomeric golgi complex 2 Homo sapiens 226-231 12486415-10 2002 Some of the new options for reducing LDL-C levels that may be available in the near future include 2 new statins, pitavastatin and rosuvastatin. Rosuvastatin Calcium 131-143 component of oligomeric golgi complex 2 Homo sapiens 37-42 12486415-11 2002 In patients with heterozygous familial hypercholesterolemia, rosuvastatin, which is currently under review by the Food and Drug Administration (FDA), has been shown to produce significantly greater reductions in LDL-C than atorvastatin over its full dose range. Rosuvastatin Calcium 61-73 component of oligomeric golgi complex 2 Homo sapiens 212-217 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 93-105 component of oligomeric golgi complex 2 Homo sapiens 245-250 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 107-114 component of oligomeric golgi complex 2 Homo sapiens 245-250 12238638-8 2002 These preliminary results indicate that rosuvastatin is a potent cholesterol-lowering agent, capable of achieving marked reductions in LDL-C even at low doses. Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 135-140 12137448-5 2002 Rosuvastatin was also superior to all these agents in helping patients meet European Atherosclerosis Society (EAS) and National Cholesterol Education Programme (NCEP) goals for LDL-C. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 177-182 11900720-13 2002 A number of agents for reducing LDL-C levels currently in development may be available in the near future, including 2 new statins: pitavastatin and rosuvastatin. Rosuvastatin Calcium 149-161 component of oligomeric golgi complex 2 Homo sapiens 32-37 11900720-14 2002 Rosuvastatin, which is in the later stages of the US Food and Drug Administration (FDA) approval process, has been shown to produce significantly greater reductions in LDL-C levels compared with atorvastatin, simvastatin, and pravastatin, and allows more patients to meet lipid goals. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 168-173 11383378-2 2001 With each doubling of the rosuvastatin dose (1, 2.5, 5, 10, 20, 40, and 80 mg/day), there was an additional 4.5% reduction in LDL-C. Rosuvastatin Calcium 26-38 component of oligomeric golgi complex 2 Homo sapiens 126-131 11383378-4 2001 The latter percent reduction surpasses the maximal reductions reported for all other statins when used for monotherapy and suggests that rosuvastatin might enable more patients with hypercholesterolemia to achieve target LDL-C levels. Rosuvastatin Calcium 137-149 component of oligomeric golgi complex 2 Homo sapiens 221-226 11256849-2 2001 In dose-ranging studies of patients with hypercholesterolemia, the new synthetic statin rosuvastatin (formerly ZD4522) produced significant, dose-dependent reductions in LDL-C compared with placebo across a range of doses. Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 170-175 11256849-3 2001 Reductions ranged from 34% at 1 mg per day to 65% at 80 mg per day, with linear regression analysis indicating an additional 4.5% reduction in LDL-C with each doubling of the rosuvastatin dose. Rosuvastatin Calcium 175-187 component of oligomeric golgi complex 2 Homo sapiens 143-148 34307425-5 2021 In 2014, upon starting treatment with rosuvastatin for LDLc level of 7.59 mmol/L, the patient was admitted to the Emergency Room for a presumptive diagnosis of rhabdomyolysis (creatine kinase 6685 U/L) secondary to statin. Rosuvastatin Calcium 38-50 component of oligomeric golgi complex 2 Homo sapiens 55-59 25626487-10 2015 Compared to non-switchers, the adjusted least squares mean differences in the percentage change in LDL-C levels from baseline were 18.74% (p = 0.0003), 16.73% (p < 0.0001), and -0.11% (p = 0.9044) when switching from simvastatin/ezetimibe, rosuvastatin, and atorvastatin, respectively. Rosuvastatin Calcium 243-255 component of oligomeric golgi complex 2 Homo sapiens 99-104 25626487-11 2015 The odds of LDL-C goal attainment at follow-up among switchers from simvastatin/ezetimibe, rosuvastatin, and atorvastatin were 0.40 (95% CI: 0.23-0.70), 0.36 (95% CI: 0.26-0.51) and 1.03 (95% CI: 0.92-1.15) relative to non-switchers respectively. Rosuvastatin Calcium 91-103 component of oligomeric golgi complex 2 Homo sapiens 12-17 25626487-12 2015 IMPLICATIONS: Among the high risk CVD population in UK, switching to simvastatin from HET, especially rosuvastatin and simvastatin/ezetimibe, resulted in an increase in LDL-C levels and lower goal attainment. Rosuvastatin Calcium 102-114 component of oligomeric golgi complex 2 Homo sapiens 169-174 22705128-6 2012 Rosuvastatin appeared to be the most efficacious of the three statins, both for lowering LDL-C and for reaching a target level of <70 mg dl(-1) for LDL-C. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 89-94 22705128-6 2012 Rosuvastatin appeared to be the most efficacious of the three statins, both for lowering LDL-C and for reaching a target level of <70 mg dl(-1) for LDL-C. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 151-156 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Rosuvastatin Calcium 182-194 component of oligomeric golgi complex 2 Homo sapiens 134-139 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Rosuvastatin Calcium 228-240 component of oligomeric golgi complex 2 Homo sapiens 134-139 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Rosuvastatin Calcium 287-299 component of oligomeric golgi complex 2 Homo sapiens 134-139 34375677-10 2022 CONCLUSION: Addition of Evolocumab to the standard double therapy in Chinese CHD patients improved the efficacy in LDL-C reduction when compared to Rosuvastatin alone or in Rosuvastatin/Ezetimibe double therapy. Rosuvastatin Calcium 148-160 component of oligomeric golgi complex 2 Homo sapiens 115-120 29857919-6 2018 FINDINGS: At the end of the main study (week 8), LDL-C levels were significantly lower in subjects receiving combination therapy than in those receiving rosuvastatin monotherapy. Rosuvastatin Calcium 153-165 component of oligomeric golgi complex 2 Homo sapiens 49-54 32003938-4 2020 The mean +- SD percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline after 8 weeks was -52.53% +- 11.21% in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. Rosuvastatin Calcium 143-155 component of oligomeric golgi complex 2 Homo sapiens 73-78 32003938-5 2020 More patients in the rosuvastatin + amlodipine group achieved their target LDL-C goal at 8 weeks, compared with the other treatment groups (97.14%). Rosuvastatin Calcium 21-33 component of oligomeric golgi complex 2 Homo sapiens 75-80 32003938-7 2020 In hypertensive patients with dyslipidemia, combination treatment with rosuvastatin 20 mg + amlodipine 10 mg effectively reduced blood pressure and LDL-C levels while maintaining safety. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 148-153 29857919-12 2018 IMPLICATIONS: Combination therapy of ezetimibe 10 mg with varying doses of rosuvastatin that are commonly used in the clinical field improved the lipid profile and allowed more subjects to reach the LDL-C goal in primary hypercholesterolemia compared with rosuvastatin monotherapy. Rosuvastatin Calcium 75-87 component of oligomeric golgi complex 2 Homo sapiens 199-204 29201198-3 2017 The aim of current study was to investigate how the addition of ezetimibe to rosuvastatin treatment affects reductions in LDL-C, hsCRP and Lp-PLA2 in patients with acute myocardial infarction (AMI). Rosuvastatin Calcium 77-89 component of oligomeric golgi complex 2 Homo sapiens 122-127 29476887-10 2018 In comparison with other statin treatment, use of atorvastatin or rosuvastatin was associated with average LDL-C reduction of 8.0 mg/dL. Rosuvastatin Calcium 66-78 component of oligomeric golgi complex 2 Homo sapiens 107-112 29255347-13 2017 In the PD assessments, rosuvastatin and ezetimibe monotherapy reduced the LDL-C and TC levels effectively. Rosuvastatin Calcium 23-35 component of oligomeric golgi complex 2 Homo sapiens 74-79 29524865-7 2018 Network meta-analysis indicated a larger benefit for rosuvastatin compared to placebo and other statins; 50% of the effect of statins on VTE risk reduction, however, was explained by their different potencies in lowering LDL-c. Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 221-226 28836458-5 2018 Compared with atorvastatin 10 mg, rosuvastatin 5 mg (-41.70% vs. -38.67%, p = .132) and rosuvastatin 10 mg showed greater LDL-C reduction (-46.28% vs. -38.67%, p = .0002). Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 122-127 28836458-5 2018 Compared with atorvastatin 10 mg, rosuvastatin 5 mg (-41.70% vs. -38.67%, p = .132) and rosuvastatin 10 mg showed greater LDL-C reduction (-46.28% vs. -38.67%, p = .0002). Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 122-127 28836458-6 2018 LDL-C target achievement rates with rosuvastatin 5 mg, rosuvastatin 10 mg and atorvastatin 10 mg were 61.0%, 79.1% and 58.3% in the randomized phase. Rosuvastatin Calcium 36-48 component of oligomeric golgi complex 2 Homo sapiens 0-5 28836458-7 2018 In the open-label phase, LDL-C target achievement occurred in >40% with both doses of rosuvastatin. Rosuvastatin Calcium 89-101 component of oligomeric golgi complex 2 Homo sapiens 25-30 27798317-12 2017 In patients converted to rosuvastatin 5 mg daily, the mean LDL-C was 3.8 mg/dL lower than prior to conversion ( P = 0.73). Rosuvastatin Calcium 25-37 component of oligomeric golgi complex 2 Homo sapiens 59-64 29201198-10 2017 In conclusion, the addition of ezetimibe to rosuvastatin was demonstrated to further reduce LDL-C, hsCRP and Lp-PLA2 compared with rosuvastatin monotherapy in patients with AMI. Rosuvastatin Calcium 44-56 component of oligomeric golgi complex 2 Homo sapiens 92-97 28599257-6 2017 The odds to treat to LDL-C target was greater for simvastatin-ezetimibe fixed combination, simvastatin, atorvastatin and rosuvastatin, in decreasing order. Rosuvastatin Calcium 121-133 component of oligomeric golgi complex 2 Homo sapiens 21-26 28429691-7 2017 RESULTS: After 4-week treatment, atorvastatin and rosuvastatin were associated with significant reduction in TAS, OSI, total cholesterol, and LDL-C levels. Rosuvastatin Calcium 50-62 component of oligomeric golgi complex 2 Homo sapiens 142-147 28807393-7 2017 In patients without dose changes, LDL-C reduction with rosuvastatin 10 mg was significantly greater compared with atorvastatin 20 mg (-0.67 mmol/L [from 2.44 mmol/L to 1.77 mmol/L] vs -0.54 mmol/L [from 2.40 mmol/L to 1.86 mmol/L]; P = 0.008). Rosuvastatin Calcium 55-67 component of oligomeric golgi complex 2 Homo sapiens 34-39 28807393-11 2017 Compared with atorvastatin 20 mg, rosuvastatin 10 mg was associated with greater LDL-C reductions and achievement of LDL-C targets in a higher percentage of patients. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 81-86 28807393-11 2017 Compared with atorvastatin 20 mg, rosuvastatin 10 mg was associated with greater LDL-C reductions and achievement of LDL-C targets in a higher percentage of patients. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 117-122 28848611-9 2017 The STELLAR trial was based on dose-to-dose comparisons between atorvastatin and rosuvastatin efficacy in reducing LDL-C. Rosuvastatin Calcium 81-93 component of oligomeric golgi complex 2 Homo sapiens 115-120 28848611-12 2017 The DISCOVERY study involving the Asian population revealed that the percentage of patients achieving the European goals for LDL-C and TC at 12 weeks was higher in rosuvastatin group compared to atorvastatin group. Rosuvastatin Calcium 164-176 component of oligomeric golgi complex 2 Homo sapiens 125-130 27105046-11 2016 CONCLUSION: Intensive rosuvastatin therapy stabilizes hs-CRP levels, but not chemokine levels, besides lowering LDL-C levels. Rosuvastatin Calcium 22-34 component of oligomeric golgi complex 2 Homo sapiens 112-117 26969416-7 2016 Rosuvastatin 10 to 40 mg resulted in significantly greater LDL-C reductions than equal or double doses of atorvastatin and simvastatin (p <0.05). Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 59-64 26589368-7 2016 CONCLUSION: Switching from 10mg atorvastatin to 5mg rosuvastatin may be a useful therapeutic option to reduce sd LDL-C levels in Japanese hypercholesterolemic patients with T2DM. Rosuvastatin Calcium 52-64 component of oligomeric golgi complex 2 Homo sapiens 113-118 26638010-7 2016 In the baseline rosuvastatin 10 mg group, significantly greater LDL-C reductions were observed with add-on alirocumab (-50.6%) versus ezetimibe (-14.4%; p < 0.0001) and double-dose rosuvastatin (-16.3%; p < 0.0001). Rosuvastatin Calcium 16-28 component of oligomeric golgi complex 2 Homo sapiens 64-69 26638010-7 2016 In the baseline rosuvastatin 10 mg group, significantly greater LDL-C reductions were observed with add-on alirocumab (-50.6%) versus ezetimibe (-14.4%; p < 0.0001) and double-dose rosuvastatin (-16.3%; p < 0.0001). Rosuvastatin Calcium 184-196 component of oligomeric golgi complex 2 Homo sapiens 64-69 26638010-8 2016 In the baseline rosuvastatin 20 mg group, LDL-C reduction with add-on alirocumab was -36.3% compared with -11.0% with ezetimibe and -15.9% with double-dose rosuvastatin (p = 0.0136 and 0.0453, respectively; pre-specified threshold for significance p < 0.0125). Rosuvastatin Calcium 16-28 component of oligomeric golgi complex 2 Homo sapiens 42-47 26638010-10 2016 Of alirocumab-treated patients, 84.9% and 66.7% in the baseline rosuvastatin 10 and 20 mg groups, respectively, achieved risk-based LDL-C targets. Rosuvastatin Calcium 64-76 component of oligomeric golgi complex 2 Homo sapiens 132-137 26638010-12 2016 CONCLUSIONS: The addition of alirocumab to rosuvastatin provided incremental LDL-C lowering versus adding ezetimibe or doubling the rosuvastatin dose. Rosuvastatin Calcium 43-55 component of oligomeric golgi complex 2 Homo sapiens 77-82 26687694-15 2015 CONCLUSIONS: In HeFH patients aged 6-17 years, rosuvastatin 5-20 mg over 2 years significantly reduced LDL-C compared with baseline. Rosuvastatin Calcium 47-59 component of oligomeric golgi complex 2 Homo sapiens 103-108 26365713-2 2015 Rosuvastatin 10 mg daily appears to be more potent in reducing LDL-C than simvastatin 40 mg, but the relative effect of these two statin doses on hsCRP is unknown. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 63-68 26365713-7 2015 The lipid target (LDL-C <2.6 mmol/L) was achieved by 52.9 % with rosuvastatin compared with 42.6 % with simvastatin (P < 0.05). Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 18-23 26365713-9 2015 CONCLUSION: A significantly greater proportion of patients achieved LDL-C targets with rosuvastatin 10 mg compared to simvastatin 40 mg in Chinese patients with hypercholesterolaemia, but there was no significant difference in achieving hsCRP target levels with the two statins. Rosuvastatin Calcium 87-99 component of oligomeric golgi complex 2 Homo sapiens 68-73 26074319-4 2015 LSM percentage reductions in LDL-C with rosuvastatin 20 and 40 mg were greater than with atorvastatin 40 mg, overall and in each statin benefit group, and with rosuvastatin 40 mg were greater than with atorvastatin 80 mg overall and in three of the four benefit groups (all p < 0.05). Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 29-34 25864881-4 2015 Over the 12-week period following rosuvastatin initiation, serum levels of total cholesterol (TC) and LDL-c and the ratio TC/high-density lipoprotein cholesterol (HDL-c) decreased steadily (P < 0.001). Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 102-107 26721008-5 2015 The objective of this study is to compare mean reduction in serum LDL-C level after using 5mg and 10mg of rosuvastatin among T2DM patients with hypercholesterolemia. Rosuvastatin Calcium 106-118 component of oligomeric golgi complex 2 Homo sapiens 66-71 26721008-6 2015 This study will help finding lowest effective dose of rosuvastatin to achieve internationally set low density lipoprotein cholesterol (LDL-C) goals. Rosuvastatin Calcium 54-66 component of oligomeric golgi complex 2 Homo sapiens 135-140 26721008-14 2015 CONCLUSION: Rosuvastatin 5mg is as effective as 10mg in reducing the LDL-C levels in type 2 diabetic patients with hypercholesterolemia. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 69-74 25971444-6 2015 LDL-C lowering by rosuvastatin (mean 40 mg daily) could significantly decrease the volumes of CAP at follow up. Rosuvastatin Calcium 18-30 component of oligomeric golgi complex 2 Homo sapiens 0-5 25971444-8 2015 LDL-C lowering by rosuvastatin (mean 14.1 mg daily) and atorvastatin (mean 18.9 mg daily) could significantly decrease the volumes of CAP at follow up. Rosuvastatin Calcium 18-30 component of oligomeric golgi complex 2 Homo sapiens 0-5 25262434-7 2014 After 6 months, rosuvastatin (-37.6% +- 17.2%) and atorvastatin (-32.4% +- 22.4%) equally reduced low-density lipoprotein-cholesterol (LDL-C) levels (p = 0.28). Rosuvastatin Calcium 16-28 component of oligomeric golgi complex 2 Homo sapiens 135-140 25463129-6 2014 RESULTS: LDL-C percent change from baseline was -26.0 for ezetimibe added to ongoing statin therapy, -27.6 for switching from ongoing statin to ezetimibe/simvastatin, -19.7 for switching to rosuvastatin 10 mg, and -9.7 for dose doubling of the ongoing statin. Rosuvastatin Calcium 190-202 component of oligomeric golgi complex 2 Homo sapiens 9-14 25463129-7 2014 For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Rosuvastatin Calcium 219-231 component of oligomeric golgi complex 2 Homo sapiens 69-74 25262434-11 2014 CoQ10/LDL-C levels at 6 months were increased in the rosuvastatin group (+23.5%, p < 0.01) and percent changes in CoQ10/LDL-C were correlated with the myocardial salvage index (r = 0.56, p < 0.01). Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 6-11 25262434-12 2014 CONCLUSION: Rosuvastatin shows better beneficial effects on myocardial salvage than atorvastatin in STEMI patients, including long-term cardiac function, associated with increasing CoQ10/LDL-C. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 187-192 24456217-2 2014 This multicenter, open-label, randomized, parallel-group study compared the efficacy of rosuvastatin and atorvastatin on JAS2007GL LDL-C goals in Japanese patients not achieving their target goal with atorvastatin treatment. Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 131-136 24734885-9 2014 A simulation indicated that the combined treatment of ezetimibe with rosuvastatin (2.5 mg day(-1) ) led to superior clinical responses than those with high doses of rosuvastatin (5.0 mg day(-1) ) monotherapy, even in patients with higher baseline LDL-C concentrations prior to the treatment. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 247-252 25022285-4 2014 Rosuvastatin 5-20 mg/day was used to lower LDL-C levels to < 80 mg/dl. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 43-48 25022285-7 2014 RESULTS: Among the 32 subjects who completed the study, at 3 months, an average dose of rosuvastatin of 11 mg/day lowered LDL-C levels by 47% (125.2 +- 24.4 mg/dl vs. 66.7 +- 17.3 mg/dl, p < 0.001). Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 122-127 24456217-10 2014 CONCLUSIONS: Rosuvastatin is a useful treatment option for Japanese patients who are not achieving their JAS2007GL LDL-C goal with atorvastatin. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 115-120 24632963-10 2014 LDL-C was reduced by 48.1% in the rosuvastatin group and 27.9% in the pravastatin group. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 0-5 24886532-8 2014 LDL-C lowering by rosuvastatin (mean 33 mg daily) and atorvastatin (mean 60 mg daily) could significantly decrease the volumes of CAP at follow up (SMD -0.162 mm3, 95% CI: -0.234 ~ -0.081, p = 0.000; SMD -0.101, 95% CI: -0.184 ~ -0.019, p = 0.016; respectively). Rosuvastatin Calcium 18-30 component of oligomeric golgi complex 2 Homo sapiens 0-5 24886532-10 2014 CONCLUSIONS: Intensive lowering LDL-C (rosuvastatin mean 33 mg daily and atorvastatin mean 60 mg daily) with >17 months of duration could lead to the regression of CAP, LDL-C level should be reduced by >40% or to a target level <78 mg/dL for regressing CAP. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 32-37 24886532-10 2014 CONCLUSIONS: Intensive lowering LDL-C (rosuvastatin mean 33 mg daily and atorvastatin mean 60 mg daily) with >17 months of duration could lead to the regression of CAP, LDL-C level should be reduced by >40% or to a target level <78 mg/dL for regressing CAP. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 172-177 24632963-11 2014 The rate of achieving the LDL-C goal was significantly greater in the rosuvastatin group compared with the pravastatin group (P < 0.001). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 26-31 24800084-13 2014 There was a greater absolute and percent reduction in serum LDL-C levels with rosuvastatin as compared to atorvastatin (0.96 versus 0.54 mg/dL; P = 0.011 and 24.34 versus 13.66%; P = 0.045), whereas reduction in all other fractions was equal. Rosuvastatin Calcium 78-90 component of oligomeric golgi complex 2 Homo sapiens 60-65 24800084-16 2014 Rosuvastatin produces a greater reduction in serum LDL-C levels and should therefore be preferred over atorvastatin. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 51-56 23442255-8 2013 Low density lipoprotein cholesterol (LDL-c) was higher and decreased significantly in the rosuvastatin group (p < 0.01). Rosuvastatin Calcium 90-102 component of oligomeric golgi complex 2 Homo sapiens 0-35 23644489-7 2013 RESULTS: LDL-C <100 mg/dl was achieved by 53.7-85.5% of patients on rosuvastatin 10-40 mg and 43.3-80.0% of those on atorvastatin 10-80 mg, whereas LDL-C <70 mg/dl was achieved by 4.5-44.0% of rosuvastatin-treated patients and 6.5-41.4% of those on atorvastatin. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 9-14 23644489-7 2013 RESULTS: LDL-C <100 mg/dl was achieved by 53.7-85.5% of patients on rosuvastatin 10-40 mg and 43.3-80.0% of those on atorvastatin 10-80 mg, whereas LDL-C <70 mg/dl was achieved by 4.5-44.0% of rosuvastatin-treated patients and 6.5-41.4% of those on atorvastatin. Rosuvastatin Calcium 199-211 component of oligomeric golgi complex 2 Homo sapiens 9-14 23644489-8 2013 Similar differences in efficacy favouring rosuvastatin over equal or double doses of atorvastatin were observed across the range of baseline LDL-C levels for both LDL-C goals, being more pronounced at higher baseline values. Rosuvastatin Calcium 42-54 component of oligomeric golgi complex 2 Homo sapiens 141-146 23644489-8 2013 Similar differences in efficacy favouring rosuvastatin over equal or double doses of atorvastatin were observed across the range of baseline LDL-C levels for both LDL-C goals, being more pronounced at higher baseline values. Rosuvastatin Calcium 42-54 component of oligomeric golgi complex 2 Homo sapiens 163-168 23442255-8 2013 Low density lipoprotein cholesterol (LDL-c) was higher and decreased significantly in the rosuvastatin group (p < 0.01). Rosuvastatin Calcium 90-102 component of oligomeric golgi complex 2 Homo sapiens 37-42 22065156-8 2012 Among those allocated to rosuvastatin, greater reductions in LDL-C were associated with greater increases in PCSK9 on both absolute and relative scales (r=-0.15, P<0.0005). Rosuvastatin Calcium 25-37 component of oligomeric golgi complex 2 Homo sapiens 61-66 23288881-4 2013 The LDL-C reduction was numerically greater when switching to EZ/S versus switching to rosuvastatin (p = 0.060). Rosuvastatin Calcium 87-99 component of oligomeric golgi complex 2 Homo sapiens 4-9 24265554-0 2013 Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Rosuvastatin Calcium 115-127 component of oligomeric golgi complex 2 Homo sapiens 11-16 24265554-5 2013 RESULTS: LDL-C reductions from baseline and goal attainment improved substantially in patients treated with ezetimibe added onto simvastatin, atorvastatin, or rosuvastatin therapy (n=2,312) versus those (n=13,053) who titrated these statins. Rosuvastatin Calcium 159-171 component of oligomeric golgi complex 2 Homo sapiens 9-14 24265554-6 2013 In multivariable models, percent change from baseline in LDL-C was -13.1% to -14.8% greater for those who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus those who titrated. Rosuvastatin Calcium 157-169 component of oligomeric golgi complex 2 Homo sapiens 57-62 24265554-7 2013 The odds of attaining LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) increased by 2.6-3.2-fold and 2.5-3.1-fold, respectively, in patients who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus titrating statins. Rosuvastatin Calcium 198-210 component of oligomeric golgi complex 2 Homo sapiens 22-27 24265554-8 2013 CONCLUSION: CHD/CHD risk-equivalent patients in a large US managed-care database, who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin, had greater LDL-C reductions and goal attainment than those who uptitrated these statin therapies. Rosuvastatin Calcium 137-149 component of oligomeric golgi complex 2 Homo sapiens 163-168 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 component of oligomeric golgi complex 2 Homo sapiens 256-271 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 component of oligomeric golgi complex 2 Homo sapiens 273-278 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Rosuvastatin Calcium 240-252 component of oligomeric golgi complex 2 Homo sapiens 128-163 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Rosuvastatin Calcium 240-252 component of oligomeric golgi complex 2 Homo sapiens 165-170 22534644-4 2012 The FXR -1G>T SNP was not associated with baseline lipids but was significantly associated with the LDL cholesterol (LDL-C) and total cholesterol response to rosuvastatin. Rosuvastatin Calcium 161-173 component of oligomeric golgi complex 2 Homo sapiens 103-118 22534644-6 2012 The association between the FXR polymorphism and the LDL-C response to rosuvastatin remained significant after adjusting for other covariants. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 53-58 22534644-7 2012 This association of the variant allele of the FXR -1G>T polymorphism with a greater LDL-C response to rosuvastatin may suggest that this polymorphism influences the expression of the hepatic efflux transporters involved in biliary excretion of rosuvastatin. Rosuvastatin Calcium 105-117 component of oligomeric golgi complex 2 Homo sapiens 87-92 22534644-7 2012 This association of the variant allele of the FXR -1G>T polymorphism with a greater LDL-C response to rosuvastatin may suggest that this polymorphism influences the expression of the hepatic efflux transporters involved in biliary excretion of rosuvastatin. Rosuvastatin Calcium 247-259 component of oligomeric golgi complex 2 Homo sapiens 87-92 22331829-3 2012 METHODS AND RESULTS: A genome-wide association study of LDL-C response was performed among a total of 6989 men and women of European ancestry who were randomly allocated to either rosuvastatin 20 mg daily or placebo. Rosuvastatin Calcium 180-192 component of oligomeric golgi complex 2 Homo sapiens 56-61 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 component of oligomeric golgi complex 2 Homo sapiens 88-93 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 component of oligomeric golgi complex 2 Homo sapiens 237-242 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 component of oligomeric golgi complex 2 Homo sapiens 237-242 22331829-5 2012 Median LDL-C reductions on rosuvastatin were 40, 48, 51, 55, 60, and 64 mg/dL, respectively, among those inheriting increasing numbers of LDL-lowering alleles for SNPs at these 4 loci (P trend=6.2x10(-20)), such that each allele approximately doubled the odds of percent LDL-C reduction greater than the trial median (odds ratio, 1.9; 95% confidence interval, 1.8-2.1; P=5.0x10(-41)). Rosuvastatin Calcium 27-39 component of oligomeric golgi complex 2 Homo sapiens 7-12 22230323-4 2012 Among 3386 rosuvastatin-allocated individuals, both CRP and LDL-C levels were reduced by 50% after 12 months of therapy (P<0.001 for both) and essentially uncorrelated (r(2)<0.03). Rosuvastatin Calcium 11-23 component of oligomeric golgi complex 2 Homo sapiens 60-65 22230323-9 2012 CONCLUSIONS: The genetic determinants of rosuvastatin-induced CRP reduction differ from, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL-C reduction. Rosuvastatin Calcium 163-175 component of oligomeric golgi complex 2 Homo sapiens 184-189 22065156-10 2012 CONCLUSIONS: In this randomized trial, rosuvastatin increased plasma concentration of PCSK9 in proportion to the magnitude of LDL-C reduction; the LDL-C response to statin could not be inferred by PCSK9 concentrations. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 126-131 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Rosuvastatin Calcium 62-74 component of oligomeric golgi complex 2 Homo sapiens 128-143 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 71-76 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 157-162 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Rosuvastatin Calcium 114-126 component of oligomeric golgi complex 2 Homo sapiens 53-58 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Rosuvastatin Calcium 114-126 component of oligomeric golgi complex 2 Homo sapiens 180-185 21492764-2 2011 OBJECTIVES: The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial. Rosuvastatin Calcium 182-194 component of oligomeric golgi complex 2 Homo sapiens 150-155 21492764-2 2011 OBJECTIVES: The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial. Rosuvastatin Calcium 325-337 component of oligomeric golgi complex 2 Homo sapiens 150-155 21492764-9 2011 CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein >=2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events. Rosuvastatin Calcium 104-116 component of oligomeric golgi complex 2 Homo sapiens 31-36 21492764-9 2011 CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein >=2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events. Rosuvastatin Calcium 104-116 component of oligomeric golgi complex 2 Homo sapiens 150-155 21189273-10 2011 One year after starting a statin therapy, patients who received atorvastatin or rosuvastatin had significantly greater decreases in total cholesterol, LDL-C, and non-HDL-C than patients on pravastatin. Rosuvastatin Calcium 80-92 component of oligomeric golgi complex 2 Homo sapiens 151-156 21189273-11 2011 The likelihood of reaching NCEP goals for LDL-C levels was higher with the use of rosuvastatin (OR 2.1; P = .03) and atorvastatin (odds ratio [OR], 2.1; P = .001) compared with that of pravastatin. Rosuvastatin Calcium 82-94 component of oligomeric golgi complex 2 Homo sapiens 42-47 21189273-14 2011 CONCLUSIONS: our findings suggest that atorvastatin and rosuvastatin are preferable to pravastatin for treatment of HIV-infected patients with dyslipidemia, due to greater declines in total cholesterol, LDL-C, and non-HDL-C, with similar lower toxicity rates. Rosuvastatin Calcium 56-68 component of oligomeric golgi complex 2 Homo sapiens 203-208 20971747-7 2011 CONCLUSION: In primary prevention patients with elevated hs C-reactive protein who have high global cardiovascular risk (10-year Framingham risk score >20% or SCORE risk >=5%), but LDL-C levels not requiring pharmacologic treatment, rosuvastatin 20 mg significantly reduced major cardiovascular events. Rosuvastatin Calcium 239-251 component of oligomeric golgi complex 2 Homo sapiens 187-192 21921413-6 2011 RESULTS: Rosuvastatin effectively reduced total cholesterol, LDL-C, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C) levels, and the LDL-C/ HDL-C ratio in the rosuvastatin group. Rosuvastatin Calcium 9-21 component of oligomeric golgi complex 2 Homo sapiens 61-66 22291492-4 2010 Given the potency of rosuvastatin to lower LDL-C and fenofibrate"s effectiveness in lowering TG, the use of this specific combination may be desirable in treating mixed dyslipidemia. Rosuvastatin Calcium 21-33 component of oligomeric golgi complex 2 Homo sapiens 43-48 20953684-5 2010 RESULTS: Treatment with rosuvastatin + fenofibric acid resulted in statistically significant greater improvements in HDL-C (23.0% vs. 12.4%; P < 0.001) and TG (-40.3% vs. -17.5%; P < 0.001), compared with rosuvastatin monotherapy; and LDL-C (-28.7% vs. -4.1%; P < 0.001), compared with fenofibric acid monotherapy. Rosuvastatin Calcium 24-36 component of oligomeric golgi complex 2 Homo sapiens 241-246 21122696-5 2010 The difference in percent change in LDL-C levels from baseline were 25.2 (95% confidence interval 21.2-29.2), 13.0 (6.0-20.0), and 3.1 (0.3-5.9) greater in switchers to simvastatin in the E/S, rosuvastatin, and atorvastatin comparisons, respectively, after adjusting for age, sex, and starting dose of the initial therapy. Rosuvastatin Calcium 193-205 component of oligomeric golgi complex 2 Homo sapiens 36-41 21122696-6 2010 For switchers, the percent of patients at LDL-C <100 mg/dL at follow-up decreased from 83.5% to 63.8% in the E/S, 67.7% to 52.7% in the rosuvastatin, and 65.1% to 60.2% in the atorvastatin cohorts. Rosuvastatin Calcium 139-151 component of oligomeric golgi complex 2 Homo sapiens 42-47 20679960-6 2010 This study identified some genetic determinants of LDL-C response to rosuvastatin in Chinese patients, which need to be replicated in other populations. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 51-56 20130569-0 2010 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Rosuvastatin Calcium 90-102 component of oligomeric golgi complex 2 Homo sapiens 42-77 20130569-3 2010 In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. Rosuvastatin Calcium 72-84 component of oligomeric golgi complex 2 Homo sapiens 199-204 20130569-4 2010 As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin. Rosuvastatin Calcium 206-218 component of oligomeric golgi complex 2 Homo sapiens 120-125 20195400-7 2010 CONCLUSIONS: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 101-106 20335146-0 2010 [Effects of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hypertensive patients with mild LDL-C elevation]. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 160-165 20335146-4 2010 RESULTS: After 12 months of treatment, LDL-C was decreased by 33.2% in rosuvastatin group but remained unchanged in patients without rosuvastatin treatment. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 39-44 20335146-4 2010 RESULTS: After 12 months of treatment, LDL-C was decreased by 33.2% in rosuvastatin group but remained unchanged in patients without rosuvastatin treatment. Rosuvastatin Calcium 133-145 component of oligomeric golgi complex 2 Homo sapiens 39-44 19838098-4 2010 Rosuvastatin is the statin most effective on low-density lipoprotein cholesterol (LDL-c) in non-HIV patients. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 45-80 19838098-4 2010 Rosuvastatin is the statin most effective on low-density lipoprotein cholesterol (LDL-c) in non-HIV patients. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 82-87 19838098-10 2010 The median percentage changes in the rosuvastatin and pravastatin arms were -37 and -19% for LDL-c (P < 0.001), respectively, and -19 and -7% for triglycerides (P = 0.035), respectively. Rosuvastatin Calcium 37-49 component of oligomeric golgi complex 2 Homo sapiens 93-98 21090830-12 2010 Rosuvastatin + ezetimibe, simvastatin + ezetimibe, and atorvastatin + ezetimibe were the most cost-effective combination therapies for reducing LDL-C levels. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 144-149 21090830-13 2010 Rosuvastatin was the most cost-effective statin for achieving the LDL-C therapeutic goal in patients at high risk for CHD, with a mean cost per patient of Euro 516. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 66-71 21090831-0 2010 Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 125-130 21090831-7 2010 In addition, rosuvastatin was associated with reductions in LDL-C and hsCRP levels, and these reductions appeared to occur independently of each other. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 60-65 21090831-8 2010 The greatest clinical benefit was observed in rosuvastatin recipients achieving an LDL-C level of <1.8 mmol/L (<70 mg/dL) and an hsCRP level of <2 mg/L or, even more so, <1 mg/L. Rosuvastatin Calcium 46-58 component of oligomeric golgi complex 2 Homo sapiens 83-88 18996523-4 2009 RESULTS: Combination therapy with ABT-335+rosuvastatin 10 mg resulted in significantly (p<0.001) greater improvements in HDL-C (20.3% vs. 8.5%) and TG (-47.1% vs. -24.4%) compared to rosuvastatin 10 mg; and LDL-C (-37.2% vs. -6.5%) compared to ABT-335. Rosuvastatin Calcium 42-54 component of oligomeric golgi complex 2 Homo sapiens 210-215 19916726-0 2009 Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 42-47 19916726-0 2009 Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 59-64 19916726-6 2009 RESULTS: Seven studies consistently showed that diverse patients from different geographic regions who were newly initiated on rosuvastatin had significantly greater reduction in low-density lipoprotein cholesterol (LDL-C) (29-52%) compared with patients treated with other statins (16-43%). Rosuvastatin Calcium 127-139 component of oligomeric golgi complex 2 Homo sapiens 216-221 19916726-7 2009 LDL-C goal attainment as recommended by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III or European Society of Cardiology (ESC) guidelines was consistently and significantly higher among patients treated with rosuvastatin (64-81%) compared with patients treated with other statins (34-73%). Rosuvastatin Calcium 239-251 component of oligomeric golgi complex 2 Homo sapiens 0-5 19916726-8 2009 Rosuvastatin-treated patients with diabetes or HIV or who were elderly had significantly greater LDL-C reduction and LDL-C goal attainment compared with patients treated with other statins. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 97-102 19916726-8 2009 Rosuvastatin-treated patients with diabetes or HIV or who were elderly had significantly greater LDL-C reduction and LDL-C goal attainment compared with patients treated with other statins. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 117-122 19916726-10 2009 CONCLUSIONS: There is a strong and consistent body of evidence demonstrating the effectiveness of rosuvastatin in lowering LDL-C and LDL-C goal attainment in real life compared with other statins at commonly prescribed doses, which reflects the existing evidence from clinical trials. Rosuvastatin Calcium 98-110 component of oligomeric golgi complex 2 Homo sapiens 123-128 19916726-10 2009 CONCLUSIONS: There is a strong and consistent body of evidence demonstrating the effectiveness of rosuvastatin in lowering LDL-C and LDL-C goal attainment in real life compared with other statins at commonly prescribed doses, which reflects the existing evidence from clinical trials. Rosuvastatin Calcium 98-110 component of oligomeric golgi complex 2 Homo sapiens 133-138 19745745-4 2009 There were statistically significant differences for simvastatin versus rosuvastatin, respectively, for mean LDLc 2.03 mmol/l (78 mg/dl) versus 1.94 mmol/l (75 mg/dl; P = 0.009) and also mean TC 3.88 mmol/l (150 mg/dl) versus 3.75 mmol/l (145 mg/dl; P = 0.005). Rosuvastatin Calcium 72-84 component of oligomeric golgi complex 2 Homo sapiens 109-113 19745745-5 2009 A post-hoc analysis showed higher achievement of the new ESC, American Heart Association and American College of Cardiology optimal lipid target of LDLc less than 1.81 mmol/l (70 mg/dl) with rosuvastatin (45.0%) compared with simvastatin (37.8%; OR: 1.37; 95% CI: 1.09-1.72; P = 0.007). Rosuvastatin Calcium 191-203 component of oligomeric golgi complex 2 Homo sapiens 148-152 19729865-1 2009 AIMS: Rosuvastatin is more efficacious than other statins in lowering low-density lipoprotein cholesterol (LDL-C). Rosuvastatin Calcium 6-18 component of oligomeric golgi complex 2 Homo sapiens 107-112 19729865-8 2009 In statin-naive patients, rosuvastatin significantly reduced LDL-C, total cholesterol, and triglycerides by 39.9%, 28.8%, and 9.2%, respectively (p<0.001). Rosuvastatin Calcium 26-38 component of oligomeric golgi complex 2 Homo sapiens 61-66 19729865-13 2009 CONCLUSION: Rosuvastatin was well tolerated and effective in lowering LDL-C in hypercholesterolemic Asian patients. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 70-75 19729865-14 2009 Patients whose LDL-C levels were suboptimal on other statins improved their levels and more achieved LDL-C goals after switching to rosuvastatin. Rosuvastatin Calcium 132-144 component of oligomeric golgi complex 2 Homo sapiens 15-20 19729865-14 2009 Patients whose LDL-C levels were suboptimal on other statins improved their levels and more achieved LDL-C goals after switching to rosuvastatin. Rosuvastatin Calcium 132-144 component of oligomeric golgi complex 2 Homo sapiens 101-106 19174696-7 2009 CONCLUSION: Rosuvastatin 10/20 mg daily enables the majority of patients to achieve LDL-C less than 115 mg/dl within 3 months. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 84-89 18996523-5 2009 Similarly, significantly (p<0.001) greater improvements were observed with ABT-335+rosuvastatin 20 mg in HDL-C (19.0% vs. 10.3%) and TG (-42.9% vs. -25.6%) compared to rosuvastatin 20 mg; and LDL-C (-38.8% vs. -6.5%) compared to ABT-335 monotherapy. Rosuvastatin Calcium 86-98 component of oligomeric golgi complex 2 Homo sapiens 195-200 19997842-4 2009 RESULTS: During the follow-up period of 4-12 weeks, LDL-C levels were reduced by a median of 27-31% of baseline values (mean 153.1 +/- 33.5 mg/dl) mainly regardless of previous statin therapy (rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, and lovastatin) and dosing (pooled median values). Rosuvastatin Calcium 193-205 component of oligomeric golgi complex 2 Homo sapiens 52-57 21291777-0 2008 Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Rosuvastatin Calcium 52-64 component of oligomeric golgi complex 2 Homo sapiens 102-107 18489494-4 2008 RESULTS: Of 10,421 eligible patients, % LDL-C reduction was significantly greater (P < 0.001) with rosuvastatin (-31.6%) than other statins (-13.9 to -21.9%). Rosuvastatin Calcium 102-114 component of oligomeric golgi complex 2 Homo sapiens 40-45 18489494-5 2008 Percentage of patients at moderate/high risk attaining LDL-C goal was higher (P < 0.001) for rosuvastatin (76.1%) versus other statins (57.6-72.6%). Rosuvastatin Calcium 96-108 component of oligomeric golgi complex 2 Homo sapiens 55-60 18489494-8 2008 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and less costly in lowering LDL-C and LDL-C goal attainment compared with atorvastatin. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 94-99 18489494-8 2008 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and less costly in lowering LDL-C and LDL-C goal attainment compared with atorvastatin. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 104-109 18578957-6 2008 Average LDL-C reductions were 48%, 42%, 39%, and 32% at mean doses of 11 mg rosuvastatin, 17 mg atorvastatin, 22 mg simvastatin and 35 mg pravastatin, respectively. Rosuvastatin Calcium 76-88 component of oligomeric golgi complex 2 Homo sapiens 8-13 18578957-9 2008 CONCLUSIONS: In a real life setting, both LDL-C reduction and the proportion of patients attaining cholesterol goals appear to be significantly increased among users of rosuvastatin compared to other statins. Rosuvastatin Calcium 169-181 component of oligomeric golgi complex 2 Homo sapiens 42-47 21291725-5 2008 RESULTS: E/S provided greater improvements than atorvastatin or rosuvastatin in LDL-C, TC, HDL-C (vs atorvastatin only), non-HDL-C, LDL-C:HDL-C, TC:HDL-C, and ApoB in all disease subgroups. Rosuvastatin Calcium 64-76 component of oligomeric golgi complex 2 Homo sapiens 80-85 21291725-7 2008 A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 172-177 21291725-7 2008 A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 185-190 21291725-7 2008 A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 185-190 18690760-3 2008 We compared the actions of rosuvastatin and atorvastatin, administered at the low dosages of 10 and 20 mg/day, respectively, in reducing plasma LDL-C levels and their effects on other components of the atherogenic lipid profile in patients with primary hypercholesterolemia. Rosuvastatin Calcium 27-39 component of oligomeric golgi complex 2 Homo sapiens 144-149 18690760-5 2008 RESULTS: At 48 weeks, rosuvastatin 10 mg/day was associated with a significantly greater reduction in plasma LDL-C levels compared with atorvastatin 20 mg/day (-44.32% vs -30%; p < 0.005). Rosuvastatin Calcium 22-34 component of oligomeric golgi complex 2 Homo sapiens 109-114 18690760-8 2008 CONCLUSION: In high-risk patients with primary hypercholesterolemia, rosuvastatin 10 mg/day was more efficacious than atorvastatin 20 mg/day in reducing plasma LDL-C levels, enabling goal LDL-C levels to be achieved and improving other lipid parameters. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 160-165 18690760-8 2008 CONCLUSION: In high-risk patients with primary hypercholesterolemia, rosuvastatin 10 mg/day was more efficacious than atorvastatin 20 mg/day in reducing plasma LDL-C levels, enabling goal LDL-C levels to be achieved and improving other lipid parameters. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 188-193 18434729-4 2008 RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin Calcium 79-91 component of oligomeric golgi complex 2 Homo sapiens 128-133 18434729-4 2008 RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin Calcium 79-91 component of oligomeric golgi complex 2 Homo sapiens 188-193 18434729-4 2008 RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin Calcium 79-91 component of oligomeric golgi complex 2 Homo sapiens 188-193 18434729-7 2008 CONCLUSION: Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 201-206 18158079-3 2007 OBJECTIVE: The aim of this study was to determine if, in routine clinical practice, a lower rate of titration is observed among rosuvastatin patients who achieved the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) target low-density lipoprotein cholesterol (LDL-C) goals as compared with patients achieving the target LDL-C goals on other statins. Rosuvastatin Calcium 128-140 component of oligomeric golgi complex 2 Homo sapiens 254-289 18158079-3 2007 OBJECTIVE: The aim of this study was to determine if, in routine clinical practice, a lower rate of titration is observed among rosuvastatin patients who achieved the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) target low-density lipoprotein cholesterol (LDL-C) goals as compared with patients achieving the target LDL-C goals on other statins. Rosuvastatin Calcium 128-140 component of oligomeric golgi complex 2 Homo sapiens 291-296 18158079-3 2007 OBJECTIVE: The aim of this study was to determine if, in routine clinical practice, a lower rate of titration is observed among rosuvastatin patients who achieved the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) target low-density lipoprotein cholesterol (LDL-C) goals as compared with patients achieving the target LDL-C goals on other statins. Rosuvastatin Calcium 128-140 component of oligomeric golgi complex 2 Homo sapiens 351-356 18158079-12 2007 Among patients attaining the target LDL-C goal, significantly fewer rosuvastatin patients (8.3%) had titration compared with atorvastatin (17.0%), simvastatin (20.0%), pravastatin (20.7%), and lovastatin (23.5%) (all, P < 0.05). Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 36-41 18158079-15 2007 CONCLUSION: Our study found that rosuvastatin patients who attained the NCEP ATP III target LDL-C goal had significantly lower titration rates than patients receiving other statins. Rosuvastatin Calcium 33-45 component of oligomeric golgi complex 2 Homo sapiens 92-97 17996658-0 2007 Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Rosuvastatin Calcium 113-125 component of oligomeric golgi complex 2 Homo sapiens 37-42 17996658-0 2007 Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Rosuvastatin Calcium 113-125 component of oligomeric golgi complex 2 Homo sapiens 55-60 17996658-15 2007 After controlling for covariates, rosuvastatin-treated patients had a 35.8% decrease in LDL-C from baseline, which was significantly greater compared with patients in the atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin (29.3%, 21.9%, 22.5%, 22.0%, and 24.9%, respectively; P < 0.05) groups. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 88-93 17996658-18 2007 CONCLUSION: In this elderly patient population, rosuvastatin was a more effective treatment for reducing LDL-C levels and attaining NCEP ATP III LDL-C goals than the other statins. Rosuvastatin Calcium 48-60 component of oligomeric golgi complex 2 Homo sapiens 105-110 17996658-18 2007 CONCLUSION: In this elderly patient population, rosuvastatin was a more effective treatment for reducing LDL-C levels and attaining NCEP ATP III LDL-C goals than the other statins. Rosuvastatin Calcium 48-60 component of oligomeric golgi complex 2 Homo sapiens 145-150 17655813-1 2007 OBJECTIVE: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 126-131 17655813-1 2007 OBJECTIVE: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 137-142 17655813-1 2007 OBJECTIVE: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus. Rosuvastatin Calcium 53-56 component of oligomeric golgi complex 2 Homo sapiens 126-131 17655813-5 2007 RSV patients had significantly higher (p < 0.05) baseline mean LDL-C levels (138 vs. 117-131 mg/dL), lower average starting dose (11.7 vs. 17.0-63.7 mg) and were younger (p < 0.005) than patients on other statins (mean age 61 vs. 63-69 years). Rosuvastatin Calcium 0-3 component of oligomeric golgi complex 2 Homo sapiens 66-71 17655813-6 2007 Percent LDL-C reduction was significantly greater (p < 0.0001) with RSV (28.4%) compared to ATV (22.5%), SMV (20.1%), PRV (13.7%), FLV (15.8%), and LOV (17.3%). Rosuvastatin Calcium 71-74 component of oligomeric golgi complex 2 Homo sapiens 8-13 17655813-8 2007 CONCLUSIONS: Rosuvastatin was more effective in lowering LDL-C and achieving LDL-C treatment goals in the diabetes mellitus population as compared to other statins in real-world clinical practice setting. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 57-62 17655813-8 2007 CONCLUSIONS: Rosuvastatin was more effective in lowering LDL-C and achieving LDL-C treatment goals in the diabetes mellitus population as compared to other statins in real-world clinical practice setting. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 77-82 17484092-6 2007 The primary objective of this study was to compare the efficacy of rosuvastatin with that of atorvastatin in achieving an LDL-C goal of < 1.00 g/1 at 12 weeks. Rosuvastatin Calcium 67-79 component of oligomeric golgi complex 2 Homo sapiens 122-127 17484092-9 2007 At 12 weeks, LDL-C goal was reached by 211 of the 411 patients treated with rosuvastatin (51.3%) and 119 of 379 patients treated with atorvastatin (31.4%), the difference being statistically significant (p < 0.0001). Rosuvastatin Calcium 76-88 component of oligomeric golgi complex 2 Homo sapiens 13-18 17484092-15 2007 Therefore, in high risk patients treated by primary care cardiologists, rosuvastatin allows a significantly greater proportion to reach the LDL-C goal of < 1.00 g/l compared to atorvastatin at the same dose. Rosuvastatin Calcium 72-84 component of oligomeric golgi complex 2 Homo sapiens 140-145 17112329-7 2006 RESULTS: Of the 775 eligible patients, rosuvastatin patients had higher baseline LDL-C levels (156 mg/dL vs 142 mg/dL or 137 mg/dL, respectively) compared with atorvastatin or simvastatin. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 81-86 17112329-8 2006 Adjusted for baseline factors, percent LDL-C reduction was significantly greater with rosuvastatin versus atorvastatin or simvastatin (37% vs 28% or 27%, respectively; P <.05). Rosuvastatin Calcium 86-98 component of oligomeric golgi complex 2 Homo sapiens 39-44 17112329-13 2006 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and cost-effective in lowering LDL-C and in attainment of ATP III LDL-C goals compared with atorvastatin or simvastatin among high-risk patients. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 97-102 17112329-13 2006 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and cost-effective in lowering LDL-C and in attainment of ATP III LDL-C goals compared with atorvastatin or simvastatin among high-risk patients. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 132-137 17212997-5 2006 RESULTS: Rosuvastatin 5 mg is significantly (P < 0.001) more effective at reducing low-density lipoprotein cholesterol (LDL-C) and total cholesterol (42% and 30%) levels compared with atorvastatin 10 mg (36% and 27%), simvastatin 20 mg (36% and 25%), and pravastatin 20 mg (27% and 19%). Rosuvastatin Calcium 9-21 component of oligomeric golgi complex 2 Homo sapiens 123-128 17212997-9 2006 CONCLUSIONS: Rosuvastatin 5 mg is well tolerated and has beneficial effects across the atherogenic lipid profile by reducing LDL-C and total cholesterol, raising high-density lipoprotein cholesterol, and helping a greater proportion of patients reach their LDL-C goals. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 125-130 17212997-9 2006 CONCLUSIONS: Rosuvastatin 5 mg is well tolerated and has beneficial effects across the atherogenic lipid profile by reducing LDL-C and total cholesterol, raising high-density lipoprotein cholesterol, and helping a greater proportion of patients reach their LDL-C goals. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 257-262 23555375-4 2009 RESULTS: LDL-C was lowered by -40.3% (from 160.3 to 95.1 mg / dL) in the rosuvastatin group and -22.9% (from 162.9 to 126.0 mg / dL) in the pravastatin group, at week 8 (P < 0.001 vs. pravastatin). Rosuvastatin Calcium 73-85 component of oligomeric golgi complex 2 Homo sapiens 9-14 23555375-6 2009 The rate of achievement of the target LDL-C control level at week 8 was significantly higher in the rosuvastatin group (98.0%) than in the pravastain group (78.7%) (P = 0.003). Rosuvastatin Calcium 100-112 component of oligomeric golgi complex 2 Homo sapiens 38-43 23555375-8 2009 CONCLUSION: Rosuvastatin 2.5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than pravastatin 10 mg, and its safety profile is similar to pravastatin 10 mg. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 76-81 23555376-4 2009 RESULTS: LDL-C was lowered by -44.5% (from 170.2 to 93.3 mg / dL) in the rosuvastatin group and -41.6% (from 169.5 to 97.9 mg / dL) in the atorvastatin group, at week 8 (P = 0.002 vs. atorvastatin). Rosuvastatin Calcium 73-85 component of oligomeric golgi complex 2 Homo sapiens 9-14 23555376-10 2009 CONCLUSION: Rosuvastatin 5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than atorvastatin 10 mg, and was also well tolerated. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 74-79 18654867-16 2008 CONCLUSIONS: Rosuvastatin was effective in lowering LDL-C values in patients with hypercholesterolaemia to the 1998 European target at week 24. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 52-57 18364261-9 2008 In LLT-naive patients, rosuvastatin 10 mg/d reduced LDL-C by a mean of 48.9% from baseline (p < 0.0001) by the on-treatment analysis and by a mean of 44.2% from baseline (p < 0.0001) by the intention-to-treat analysis. Rosuvastatin Calcium 23-35 component of oligomeric golgi complex 2 Homo sapiens 52-57 21291692-0 2007 Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. Rosuvastatin Calcium 127-139 component of oligomeric golgi complex 2 Homo sapiens 21-56 21291692-9 2007 CONCLUSIONS: The combination of rosuvastatin 40 mg and ezetimibe 10 mg offers the most effective LDL-C-lowering therapy yet reported, and is helpful in achieving lipid goals and reducing C-reactive protein levels in high-risk patients with severe hypercholesterolemia, including familial hypercholesterolemia. Rosuvastatin Calcium 32-44 component of oligomeric golgi complex 2 Homo sapiens 97-102